Eribulin effective for earlier treatment of metastatic breast cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers have found eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
For the study, researchers sought to determine the activity of eribulin as an early treatment for metastatic breast cancer.
For the phase 3 study, researchers randomly assigned 1,099 women with metastatic breast cancer who had previously been treated with an anthracycline or a taxane to receive either capecitabine or eribulin as first-, second-, or third-line therapy for metastatic breast cancer.
Results showed that there was no statistical difference in overall survival between capecitabine and eribulin. In addition, a subset analysis found that eribulin may be especially active in those with triple negative metastatic breast cancer, a type of breast cancer that is particularly difficult to treat because it does not respond to hormonal therapy or HER2-targeted therapies.
The findings suggest that eribulin may have a role earlier in the course of the treatment of metastatic breast cancer.
Eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer
- Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women
- Live-streamed Videos Address End-of-Life Planning, Decision-making
- Metastatic Disease Linked to Patients Reporting Diminished QoL
- History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis
- Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|